Clinical Trials


Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

This study has been approved for marketing
Merck Sharp & Dohme Corp.

Information provided by (Responsible Party)
Merck Sharp & Dohme Corp. Identifier

First received: September 14, 2006
Last updated: April 21, 2016
Last Verified: April 2016
History of Changes


This is a treatment use study to provide early access to MK0518 for the treatment of HIV-1 infection in patients who have limited or no treatment options due to virological failure, resistance, or intolerance to multiple antiretroviral regimens. Enrollment in this study is patient driven. Investigators are not proactively assigned. There is no target sample size and duration of the study is indefinite. For information on how to enroll in the study, see link below.

Condition Intervention
HIV Infections

Drug : raltegravir

Study Type: Expanded Access   What is Expanded Access?
Official Title: Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options

Further study details as provided by Merck Sharp & Dohme Corp.:



Ages Eligible for Study: 16 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  


Inclusion Criteria:

  • HIV positive patients who have limited or no treatment options and have documented resistance

Exclusion Criteria:
  • Patient has previously been on MK0518 therapy

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00377065

Sponsors and Collaborators

Merck Sharp & Dohme Corp.


Study Director: Medical Monitor Merck Sharp & Dohme Corp.
More Information

More Information

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00377065   History of Changes  
Other Study ID Numbers: 0518-023  
Study First Received: September 14, 2006  
Last Updated: April 21, 2016  

Additional relevant MeSH terms:
HIV Infections
Raltegravir Potassium processed this data on June 01, 2020
This information is provided by